A novel LC-MS/MS approach to the pharmacokinetic study of free and bound aflibercept simultaneously


To comprehensively evaluate the pharmacokinetic (PK) characteristics of aflibercept, we established a liquid chromatography with tandem mass spectrometry (LC-MS/MS) method to determine the concentration of vascular endothelial growth factor (VEGF)-A-bound aflibercept and free aflibercept. A specific sample preparation method of nano-surface and molecular-orientation limited (nSMOL) proteolysis was performed to extract both free and bound aflibercept from plasma. The tryptic peptides unique to aflibercept and VEGF-A were selected to quantify the amounts of total aflibercept and aflibercept–VEGF complex, respectively. The method was validated by evaluating its selectivity, linearity, precision, accuracy, extraction recovery, matrix effect, and stability. It was then successfully used to quantify total and bound aflibercept concentrations in cynomolgus monkey plasma, while indirectly obtaining the concentration of free aflibercept by subtraction. The PK results of this LC-MS/MS method are comparable to the traditional enzyme-linked immunosorbent assay (ELISA) results. It is thus a reliable and complementary method for the PK evaluation of aflibercept.

Graphical abstract

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3


  1. 1.

    Vempati P, Popel AS, Gabhann FM. Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning. Cytokine Growth Factor Rev. 2014;25(1):1–19.

    CAS  Article  Google Scholar 

  2. 2.

    Napoleone F, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438(7070):967–74.

    Article  Google Scholar 

  3. 3.

    Do DV, Quan DN, Boyer D, Schmidt-Erfurth U, Brown DM, Vitti R, et al. One-year outcomes of the DA VINCI study of VEGF trap-eye in eyes with diabetic macular edema. Ophthalmology. 2012;119(8):1658–65.

    Article  Google Scholar 

  4. 4.

    Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. Ophthalmology. 2016;123(6):1351–9.

    Article  Google Scholar 

  5. 5.

    Ho AC, Scott IU, Kim SJ, Brown GC, Brown MM, Ip MS, et al. Anti–vascular endothelial growth factor pharmacotherapy for diabetic macular edema : a report by the American Academy of Ophthalmology. Ophthalmology. 2012;119(10):2179–88.

    Article  Google Scholar 

  6. 6.

    Maguire MG, Martin DF, Ying GS, Jaffe GJ, Daniel E, Grunwald JE, et al. Five-year outcomes with anti–vascular endothelial growth factor treatment of neovascular age-related macular degeneration : the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;123(8):1751–61.

    Article  Google Scholar 

  7. 7.

    Rudge JS, Holash J, Hylton D, Russell M, Jiang S, Leidich R, et al. VEGF trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci U S A. 2007;104(47):18363–70.

    CAS  Article  Google Scholar 

  8. 8.

    Thai HT, Veyrat-Follet C, Vivier N, Dubruc C, Sanderink G, Mentré F, et al. A mechanism-based model for the population pharmacokinetics of free and bound aflibercept in healthy subjects. Br J Clin Pharmacol. 2011;72(3):402–14.

    CAS  Article  Google Scholar 

  9. 9.

    Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, et al. VEGF-trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A. 2002;99(17):11393–8.

    CAS  Article  Google Scholar 

  10. 10.

    Holash J, Rudge J, Davis S, Papadopoulos N, Wiegand S, Yancopoulos G, et al. VEGF-trap: a novel, potent VEGF blocker with anti-tumor effects. Eur J Cancer. 2003;38(17):S82.

    Google Scholar 

  11. 11.

    Sarwar S, Bakbak B, Sadiq MA, Sepah YJ, Shah SM, Ibrahim M, et al. Fusion proteins: aflibercept (VEGF trap-eye). Dev Ophthalmol. 2016;55:282.

    Article  Google Scholar 

  12. 12.

    Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF trap. Br J Ophthalmol. 2015;92(5):667–8.

    Article  Google Scholar 

  13. 13.

    Walker A, Chung CW, Neu M, Burman M, Batuwangala T, Jones G, et al. Novel interaction mechanism of a domain antibody-based inhibitor of human vascular endothelial growth factor with greater potency than ranibizumab and bevacizumab and improved capacity over aflibercept*. J Biol Chem. 2016;291(11):5500–11.

    CAS  Article  Google Scholar 

  14. 14.

    Celik N, Scheulerle A, Auffarth GU, Kopitz J, Dithmar S. Intraocular pharmacokinetics of aflibercept and vascular endothelial growth factor-A. Invest Ophth Vis Sci. 2015;56(9):5574.

    CAS  Article  Google Scholar 

  15. 15.

    Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal Aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537–48.

    Article  Google Scholar 

  16. 16.

    Folprecht G, Pericay C, Saunders MP, Thomas A, Zalcberg JR. Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study. Ann Oncol. 2016;9(11):1273–9.

    Article  Google Scholar 

  17. 17.

    Zhang Q, Spellman DS, Song Y, Choi B, Hatcher NG, Tomazela D, et al. Generic automated method for liquid chromatography-multiple reaction monitoring mass spectrometry based monoclonal antibody quantitation for preclinical pharmacokinetic studies. Anal Chem. 2014;86(17):8776–84.

    CAS  Article  Google Scholar 

  18. 18.

    Heinig K, Wirz T, Schick E, Guenzi A. Bioanalysis of therapeutic peptides: differentiating between total and anti-drug antibody bound drug using liquid chromatography–tandem mass spectrometry quantitation. J Chromatogr A. 2013;1316(21):69–77.

    CAS  Article  Google Scholar 

  19. 19.

    Zheng O, Furlong MT, Steven W, Bogdan S, James T, Haiqing W, et al. Pellet digestion: a simple and efficient sample preparation technique for LC-MS/MS quantification of large therapeutic proteins in plasma. Bioanalysis. 2012;4(1):17–28.

    Article  Google Scholar 

  20. 20.

    Jiang H, Cao H, Zhang Y, Fast DM. Systematic evaluation of supported liquid extraction in reducing matrix effect and improving extraction efficiency in LC-MS/MS based bioanalysis for 10 model pharmaceutical compounds. J Chromatogr B. 2012;891–892(891–892):71–80.

    Article  Google Scholar 

  21. 21.

    Vialaret J, Broutin S, Pugnier C, Santelé S, Jaffuel A, Barnes A, et al. What sample preparation should be chosen for targeted MS monoclonal antibody quantification in human serum? Bioanalysis. 2018;10(7):723–35.

    CAS  Article  Google Scholar 

  22. 22.

    Iwamoto N, Shimomura A, Tamura K, Hamada A, Shimada T. LC-MS bioanalysis of Trastuzumab and released emtansine using nano-surface and molecular-orientation limited (nSMOL) proteolysis and liquid–liquid partition in plasma of Trastuzumab emtansine-treated breast cancer patients. J Pharm Biomed Anal. 2017;145:33–9.

    CAS  Article  Google Scholar 

  23. 23.

    Iwamoto N, Umino Y, Aoki C, Yamane N, Hamada A, Shimada T. Fully validated LCMS bioanalysis of Bevacizumab in human plasma using nano-surface and molecular-orientation limited (nSMOL) proteolysis. Drug Metab Pharmacokinet. 2016;31(1):46–50.

    CAS  Article  Google Scholar 

  24. 24.

    Iwamoto N, Yokoyama K, Takanashi M. Application of nSMOL coupled with LC-MS bioanalysis for monitoring the Fc-fusion biopharmaceuticals Etanercept and Abatacept in human serum. Pharmacol Res Perspect. 2018;6(4):e00422.

    Article  Google Scholar 

  25. 25.

    Iwamoto N, Yonezawa A, Matsubara K, Shimada T. Acceleration of nano-surface and molecular-orientation limited (nSMOL) proteolysis with acidified reduction pretreatment for quantification of Tocilizumab. J Pharm Biomed Anal. 2019;164:467–74.

    CAS  Article  Google Scholar 

  26. 26.

    Services USDoHaH. Bioanalytical method validation guidance for industry. Rockville: Food and Drug Administration; 2018.

    Google Scholar 

  27. 27.

    Tew WP, Gordon M, Murren J, Dupont J, Pezzulli S, Aghajanian C, et al. Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors. Clin Cancer Res. 2010;16(1):358.

    CAS  Article  Google Scholar 

  28. 28.

    Kut C, MacGabhann F, Popel AS. Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br J Cancer. 2007;97(7):978.

    CAS  Article  Google Scholar 

  29. 29.

    Wang SJ, Wu ST, Gokemeijer J, Fura A, Krishna M, Morin P, et al. Attribution of the discrepancy between ELISA and LC-MS/MS assay results of a PEGylated scaffold protein in post-dose monkey plasma samples due to the presence of anti-drug antibodies. Anal Bioanal Chem. 2012;402(3):1229–39.

    CAS  Article  Google Scholar 

Download references


The authors would like to thank Shimadzu Co., Ltd., for their technical help.


This work was supported by grants from the National Natural Science Foundation of China (No.81773679) and the project of Graduate Innovation Foundation of Yantai University, GIFYTU (No.YDZD1917).

Author information



Corresponding author

Correspondence to Fei Yu.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The study had been approved by the Institutional Animal Care and Use Committee with approval number IACUC-A2017033-K001-01.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material


(PDF 315 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kong, L., Liu, F., Huo, L. et al. A novel LC-MS/MS approach to the pharmacokinetic study of free and bound aflibercept simultaneously. Anal Bioanal Chem 412, 1003–1010 (2020). https://doi.org/10.1007/s00216-019-02316-w

Download citation


  • Aflibercept
  • VEGF
  • nSMOL
  • Pharmacokinetics
  • LC-MS/MS